Advisory Board and Editors Translational Medicine
Nikolaos Gkantidis
Nikolaos Gkantidis has been a full-time Senior Staff Member at the Department of Orthodontics and Dentofacial Orthopedics, University of Bern, Switzerland, since 2016. He earned the Venia Docendi (Privatdozent) title from the same institution in 2018 and the Assoc. Prof. title in 2024. Prof. Gkantidis graduated from the Dental School of the Aristotle University of Thessaloniki, Greece (2006). Subsequently, he pursued a post-graduate program in Orthodontics at the University of Athens, graduating with honours (2010), and run an orthodontic practice in Thessaloniki (2010-2016). Prof. Gkantidis completed his doctoral studies in Bern (2013) and also served as a part-time staff member of the Department (2012-2016). In 2022, he obtained a Ph.D. degree from the University of Groningen, the Netherlands.
Prof. Gkantidis has published numerous original research papers and forged national and international collaborations in key research areas, which include the development and utilization of 3D imaging techniques in clinical research and practice, the study of facial attractiveness, and the investigation of craniofacial form. For his innovative work he has received various national and international grants and awards.
Shawn M Gomez
Professor and Associate Chair for Research in the Joint Department of Biomedical Engineering at UNC-CH and NCSU and Professor in the Department of Pharmacology at UNC-CH. Previous Florence Gould Scholar and Pasteur Foundation Fellow. Current research interests in systems and synthetic biology, bioimage informatics, and network science applied to biology. Broader interests in translational medicine and the fostering of innovative solutions to problems in healthcare.
Fanglin Guan
Prof. Fanglin Guan is Dean at Xi'an Jiaotong University. He is engaged in the integrated biological research of complex diseases, including tumor microenvironment and novel immunotherapeutic modalities, and research on the mechanisms and medical applications related to tumor cell vaccines, especially for the exploration of the mechanism of determining the biomarkers of complex diseases.
David Kennedy
Our lab studies how interrelated organ systems such as heart, kidney and liver regulate cellular damage (particularly inflammation and fibrosis) and repair during the course of chronic ailments such as heart failure, hypertension, diabetes, obesity and chronic kidney disease. We are particularly interested in developing new preventative and therapeutic strategies to help people suffering from these diseases through establishing novel biomarkers and molecular diagnostics to assist risk stratification as well as identifying new drugs and drug targets and enhancing endogenous counter-regulatory mechanisms. Given our community’s ties to and dependence on the Great Lakes as a source of clean water for drinking, recreation, fishing and agriculture, our laboratory also places a special emphasis on discovering new diagnostic, preventative and therapeutic strategies targeting cellular damage caused by environmental stressors that impair our land-water-food nexus.
William A. Knaus
Director of Applied Genomics in Informatics at Center for Clinical Research in Informatics, NorthShore Research Institute Evanston, Illinois and Professor of Medicine University of Chicago. Former Evelyn Troup Hobson Professor & Founding Chair Department of Public Health Sciences, M.D., University of Virginia School of Medicine (1995-2012). Director ICU Research George Washington University School of Medicine & founder, former board member and CEO of Apache Medical Systems (Inc.) 1988-2000.
Mei-Chuan Ko
Professor in the Department of Psychiatry, University of Pittsburgh School of Medicine. My research interests involve behavioral neuropharmacology of pain and addiction, including 1) biological basis and pharmacotherapy for drug abuse and dependence and 2) neuropharmacological basis of therapeutics of analgesics and antipruritics.
Prasanna Krishnamurthy
Dr. Prasanna earned his BVSc (DVM) degree with honors from Bangalore Veterinary College and completed his Masters and PhD in Veterinary Pathology from Indian Veterinary Research Institute (India's premier institute for Veterinary Research). He completed his postdoctoral training at Northwestern University (in Dr. Raj Kishore's laboratory) and East Tennessee State University. Before joining University of Alabama at Birmingham (UAB), he held faculty appointments at the Feinberg Cardiovascular Research Institute, Northwestern University School of Medicine, Chicago, Illinois and Houston Methodist Research Institute, Texas.
As a member of the Department of Biomedical Engineering, he directs a research program focusing on understanding mechanisms of cardiovascular diseases and developing novel therapeutic strategies to promote cardiac regeneration and repair. Dr. Krishnamurthy’s laboratory is supported through funds from National Institutes of Health (NIH-R01) and American Heart Association (GIA and Postdoctoral fellowships).
Hang Fai Kwok
Prof Kwok’s research interests mainly focus on the development of novel monoclonal antibodies and venom-based peptides as prototype drugs for anticancer and anti-inflammatory therapies. In addition, Prof. Kwok’s research group is also expanding scientific knowledge and research in the areas of existing and novel cancer biomarkers such as 1) matricellular protein — OPN, 2) metalloproteinase — ADAM17 & ADAMTS5, 3) DNA replication licensing factor — MCM proteins, 4) small GTP binding protein — RAN, as well as immunotherapy markers (e.g. PD-1/PD-L1) in order to identify and validate their prognostic and therapeutic values according to the roles in hallmarks of cancer.
Julia Kzhyshkowska
1997: PhD Cancer Research Centre of the Russian Academy of Medical Sciences, Moscow.
1997-2001: Postdoc at the University of Regensburg
2001-2007: Junior group leader/PI and lecturer, University of Heidelberg.
2007- 2010:Senior group leader/PI and senior lecturer, University of Heidelberg
2010-2013: Professor, head of the Lab for Cellular and Molecular Biology of Innate Immunity;
2013-permanent: Professor, head of Department for Innate Immunity and Tolerance, University of Heidelberg.
Giuseppe Lanza
Dr. Giuseppe Lanza was born in Catania (Italy) in 1982. He currently works as a Senior Academic Researcher and Assistant Professor at the University of Catania (Italy). After graduation with honours in Medicine, he trained at the School of Neurology and got the international PhD at the same University. As visiting Clinical Research Fellow, he further trained at the Department of Neuroscience and Clinical Neurophysiology of the Newcastle University (UK). In 2013 he was selected for a Scientific Fellowship promoted by the European Federation of Neurological Societies (EFNS). From 2013 to October 2018, he worked as a Consultant Neurologist at the “Oasi Research Institute–IRCCS” in Troina (Italy), which is a Collaborating Center of the World Health Organization (WHO), and where now he currently holds the position of Chief of the Clinical Neurophysiology Research Unit. From 2015 to October 2018, he taught Neurology at the University of Enna (Italy). He has authored more than 150 publications in internationally-indexed peer-reviewed Journals and Conferences or Meetings, and he currently serves as Editor and invited Reviewer of several international Journals. More recently, he has obtained the Master of Science in Clinical Research and the National Scientific Qualification as Full Professor (procedure for the Italian University Professor recruiting, based on criteria of scientific qualification).
B Duncan X Lascelles
After graduating from the veterinary program at the University of Bristol, U.K., with honors, Dr. Lascelles completed a PhD in aspects of pre-emptive/perioperative analgesia at the University of Bristol. After an internship there, he completed his surgical residency at the University of Cambridge, U.K. and then a Fellowship in Oncological Surgery at Colorado State University. He is currently Professor in Small Animal Surgery and Pain Management at North Carolina State University.
Ning Li
Prof. Li received his Medical Doctorate in 2005 as an outstanding graduate of the Chinese Union Medical University (CUMU). In the same year, he worked in the Department of Thoracic Surgery at the Cancer Hospital of the Chinese Academy of Medical Sciences, where he served as an attending physician, deputy chief physician, and was appointed Chief Physician in 2019. He has a solid theoretical foundation and excellent research ability, and has accumulated rich clinical experience during my work. In 2017, he took over as the Director of the Office of Drug Clinical Trial Research Center, and his outstanding achievements in the management of clinical trial institutions and clinical and translational research, and is currently served as the chief expert of China GCP platform and Leading PI of international multicenter clinical trials of anti-cancer drug discovery. He is committed to new anti-tumor drug research, real-world research, full chain translation research of clinical trials, precision treatment of rare tumors and tumor big data research. His H-Index is 44 based on Web of Science. As a sub-project leader of the National 973 Major Project, the National Key R&D Program for Precision Medicine, the National Natural Science Foundation of China, the GCP platform leader, and the leader of the 13th and 14th Five-Year Innovation Project, he has undertaken many research projects.